SCHEMBL13192595

SCHEMBL13192595

CCCCCNC(=O)NCCCC/C=C\CCCCCCc1nnn[nH]1

nearest known ligand 0.64

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 18/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12989767 1.00 EPHX2 (0.64) EPHX2
SCHEMBL15686636 0.90 EPHX2 (0.53) EPHX2
SCHEMBL17278728 0.90 EPHX2 (0.58) EPHX2
SCHEMBL15644293 0.80 EPHX2 (0.68) EPHX2
SCHEMBL15686029 0.80 EPHX2 (0.60) EPHX2
SCHEMBL15686054 0.80 EPHX2 (0.60) EPHX2
SCHEMBL15686069 0.79 EPHX2 (0.66) EPHX2
SCHEMBL23479957 0.78 EPHX2 (0.81) EPHX2
SCHEMBL15109208 0.78 EPHX2 (0.81) EPHX2
SCHEMBL15249710 0.78 EPHX2 (0.81) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358968-B2 Substituted epoxyeicosatrienoic acid (EET) analogs for treatment of kidney disease THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2022-06-14 US disclosed
US-11130772-B2 CYP-eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN 2021-09-28 US disclosed
EP-3097076-B1 NOVEL CYP-EICOSANOID DERIVATIVES MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-05-08 EP disclosed
US-20170008918-A1 NOVEL CYP-EICOSANOID DERIVATIVES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-01-12 US disclosed
US-9422318-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2016-08-23 US disclosed
US-9422318-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2016-08-23 US disclosed
EP-2694470-B1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME WISCONSIN MED COLLEGE INC (US) 2016-06-01 EP disclosed
US-20150336916-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-26 US disclosed
US-20150336916-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-26 US disclosed
US-9127027-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2015-09-08 US disclosed
US-9127027-B2 Epoxyeicosatrienoic acid analogs and methods of making and using the same THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2015-09-08 US disclosed
WO-2015110262-A1 NOVEL CYP-EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2015-07-30 WO disclosed
US-20140113884-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
US-20140113884-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
WO-2012138706-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME MCW RESEARCH FOUNDATION, INC. (US) 2012-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008918-A1 NOVEL CYP-EICOSANOID DERIVATIVES CYP4F3, ALOX5, CYP4A11 EPHX2 76/4885
US-20150336916-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME PTGER1, PTGES, PTGER2 EPHX2 24/4885
US-11358968-B2 Substituted epoxyeicosatrienoic acid (EET) analogs for treatment of kidney disease FOLR1, FOLR2, SLC46A1 EPHX2 25/4885
US-20140113884-A1 EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME PTGER1, PTGES, PTGER2 EPHX2 24/4885
US-11130772-B2 CYP-eicosanoid derivatives CYP4F3, CYP4A11, CYP1A2 EPHX2 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.